Multiple sclerosis ct scan

Jump to navigation Jump to search

Multiple sclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple sclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Alternative Therapies

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Multiple sclerosis ct scan On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Multiple sclerosis ct scan

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Multiple sclerosis ct scan

CDC on Multiple sclerosis ct scan

Multiple sclerosis ct scan in the news

Blogs on Multiple sclerosis ct scan

Directions to Hospitals Treating Multiple sclerosis

Risk calculators and risk factors for Multiple sclerosis ct scan

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D. Julinka Auta Fernandes

Overview

CT scan has a limited and nonspecific role in the evaluation of suspected multiple sclerosis (MS). Conventional CT is not the preferred imaging modality for diagnosing or routinely monitoring MS. The 2026 American College of Radiology (ACR) Appropriateness Criteria rate CT head examinations as Usually Not Appropriate for the initial evaluation of suspected central nervous system demyelinating disease because CT has limited soft-tissue characterization and poor sensitivity for demyelinating lesions.[1]

CT may demonstrate nonspecific abnormalities such as brain atrophy, white-matter hypoattenuation (lucencies), or occasional contrast enhancement. These findings are neither sufficiently sensitive nor specific to establish the diagnosis of MS.[2]

The 2024 McDonald diagnostic criteria do not use conventional CT findings to demonstrate dissemination in space or dissemination in time. Magnetic resonance imaging (MRI) remains the principal imaging modality for the diagnosis and imaging follow-up of MS.[3][4]

CT scan

CT findings that have historically been described in patients with MS include:

  • Brain atrophy, which is nonspecific and may occur in established disease
  • White-matter or periventricular hypoattenuation (lucencies)
  • Occasional contrast enhancement reflecting disruption of the blood-brain barrier

These findings have low sensitivity and specificity. A conventional head CT may be normal despite demyelinating lesions being present, and any abnormality must be interpreted in the clinical context rather than as diagnostic evidence of MS.[2][5]

CT may be obtained in selected acute or emergency circumstances when the immediate purpose is to evaluate an alternative diagnosis or complication, such as intracranial hemorrhage, mass effect, or hydrocephalus, rather than to establish MS. CT may also be considered when MRI is unavailable, contraindicated, or cannot be performed promptly; however, a negative CT examination does not exclude MS.[1]

Routine CT is not recommended for monitoring MS disease activity because of its poor sensitivity for demyelinating lesions and its use of ionizing radiation. CT contrast enhancement should not be used as a substitute for MRI assessment of inflammatory disease activity.[1][4]

The previously described double delayed high-dose CT (DDHD CT) technique was historically used to increase detection of enhancing lesions. It is not included in current MS diagnostic criteria or contemporary imaging recommendations and should not be used to guide the current diagnosis or monitoring of MS.[6][7]

References

  1. 1.0 1.1 1.2 Kalnins A, Lewis LM, Soderlund KA, et al. (2026). "ACR Appropriateness Criteria® Demyelinating Diseases". J Am Coll Radiol. doi:10.1016/j.jacr.2026.02.003. PMID 41762178 Check |pmid= value (help).
  2. 2.0 2.1 Loizou LA, Rolfe EB, Hewazy H (October 1982). "Cranial computed tomography in the diagnosis of multiple sclerosis". J Neurol Neurosurg Psychiatry. 45 (10): 905–912. doi:10.1136/jnnp.45.10.905. PMC 491595. PMID 6292371.
  3. Montalban X, Lebrun-Frénay C, Oh J, et al. (October 2025). "Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria". Lancet Neurol. 24 (10): 850–865. doi:10.1016/S1474-4422(25)00270-4. PMID 40975101 Check |pmid= value (help).
  4. 4.0 4.1 Barkhof F, Reich DS, Oh J, et al. (October 2025). "2024 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI for the diagnosis of multiple sclerosis". Lancet Neurol. 24 (10): 866–879. doi:10.1016/S1474-4422(25)00304-7. PMID 40975102 Check |pmid= value (help).
  5. Weinstein MA, Lederman RJ, Rothner AD, Duchesneau PM, Norman D (December 1978). "Interval computed tomography in multiple sclerosis". Radiology. 129 (3): 689–694. doi:10.1148/129.3.689. PMID 725045.
  6. Hershey LA, Gado MH, Trotter JL (January 1979). "Computerized tomography in the diagnostic evaluation of multiple sclerosis". Ann Neurol. 5 (1): 32–39. doi:10.1002/ana.410050106. PMID 311613.
  7. Barrett L, Drayer B, Shin C (January 1985). "High-resolution computed tomography in multiple sclerosis is outdated". Ann Neurol. 17 (1): 33–38. doi:10.1002/ana.410170109. PMID 3985583.

Template:WH Template:WS